statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity

Walmart Inc. reported a 'really strong' quarter, with e-commerce sales surging 21%. Adjusted EPS was 60 cents.
read more...

Walmart, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Dr. Reshma Kewalramani, Chief Executive Officer and President, will...

Vertex to Participate in Upcoming June Investor Conferences

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jennifer Schneider, M.D., M.S., has been elected to its Board of Directors as an independent director. Dr. Schneider has more...

Jennifer Schneider Elected to Vertex Board of Directors

Pfizer is looking to build on the success of its COVID-19 vaccine rollout by introducing a direct-to-consumer medicines platform.
read more...

Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC's 'Final Trades'

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years

A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2024, and reiterated full year 2024 financial guidance. Vertex...

Vertex Reports First Quarter 2024 Financial Results

Coming up: Federal Reserve officials speak, and Disney, Palantir, and Uber report earnings

 Dania Maxwell / Los Angeles Times via Getty Images

 Key TakeawaysEarnings reports scheduled from...

What To Expect in the Markets This Week

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO (ivacaftor) for the treatment of infants down to 1 month of...

Vertex Announces European Commission Approval for KALYDECO to Treat Infants With Cystic Fibrosis Ages 1 Month and Older

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Watchers	11,175
52-Wk Low	$320.01
52-Wk High	$453.71

Volume	521,080.00
52-Wk High	$453.71
52-Wk Low	$320.01

VRTX Vertex Pharmaceuticals, Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community